An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

Area of Science:

• Pharmacology
• Oncology
• Biochemistry

Background:

• Kinase inhibitors are crucial in cancer therapy but often lack specificity, leading to toxic side effects due to structural similarities among kinases.
• The anticancer drug imatinib, while effective for chronic myeloid leukemia (targeting Bcr-Abl) and some gastrointestinal stromal tumors (GISTs, targeting C-Kit), causes cardiotoxicity via C-Abl inhibition.

Purpose of the Study:

• To engineer a modified imatinib derivative with enhanced specificity for C-Kit kinase, reduced Bcr-Abl inhibition, and additional JNK inhibition to mitigate cardiotoxicity.
• To establish a method for controlling drug specificity through molecular design.

Main Methods:

• In vitro molecular blueprint establishment using spectrophotometric and colorimetric assays.
• Kinase screening using a phage-displayed kinase library.
• Demonstration of controlled C-Kit kinase inhibition in human cell lines.
• Therapeutic evaluation in a novel GIST mouse model.

Main Results:

• The engineered imatinib derivative demonstrated hampered Bcr-Abl inhibition and refocused impact on C-Kit kinase.
• The modified compound promoted inhibition of JNK, contributing to cardiotoxicity prevention.
• Significant reduction in cardiotoxicity was observed in the GIST mouse model, alongside therapeutic impact.

Conclusions:

• The reengineered imatinib is a promising agent for treating GISTs with significantly reduced side effects.
• This study presents a novel bottom-up strategy for controlling drug specificity and improving therapeutic safety.